Clinical Trial Update: Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097 [Phase 3]

View source ↗

Summary

Open-label extension study update for a Phase 3 trial investigating a GSK epilepsy program; trial terminated with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• VRX-RET-E22-302

Snippet

Sponsor: GlaxoSmithKline | Conditions: Epilepsy | Phase 3 | Status: TERMINATED | Results posted: 2018-06-06